Without Axis I Comorbidity as a covariate
|
DOR change: baseline to post-treatment
|
SF-12 MCS
|
−0.23
|
0.11
|
−0.31
|
−2.10
|
0.04
|
R
2
adj
= 0.07
|
DOR change: baseline to 6-month follow-up
|
EDQOL Work/School
|
5.20
|
2.07
|
0.40
|
2.51
|
0.02
|
|
EDQOL Financial
|
−4.18
|
2.12
|
−0.31
|
−1.97
|
0.06
|
R
2
adj
= 0.14
|
DOR change: baseline to 12-month follow-up
|
EDQOL Work/School
|
2.71
|
1.49
|
0.29
|
1.82
|
0.08
|
R
2
adj
= 0.06
|
WSAS change: baseline to post-treatment
|
SF-12 MCS
|
−0.43
|
0.10
|
−0.55
|
−4.34
|
<0.001
|
R
2
adj
= 0.28
|
WSAS change: baseline to 6-month follow-up
|
SF-12 MCS
|
−0.38
|
0.10
|
−0.51
|
−3.61
|
0.001
|
R
2
adj
= 0.24
|
WSAS change: baseline to 12-month follow-up
|
SF-12 MCS
|
−0.33
|
0.11
|
−0.44
|
−3.00
|
0.01
|
R
2
adj
= 0.17
|
With Axis I Comorbidity as a Covariate
|
DOR change: baseline to post-treatment
|
Axis I Comorbidities
|
6.97
|
2.62
|
0.40
|
2.67
|
0.01
|
|
EDQOL Financial
|
−4.29
|
2.06
|
−0.31
|
−2.08
|
0.04
|
R
2
adj
= 0.14
|
DOR change: baseline to 6-month follow-up
|
EDQOL Work/School
|
4.91
|
2.33
|
0.35
|
2.11
|
0.04
|
|
EDQOL Financial
|
−4.36
|
2.16
|
−0.34
|
−2.02
|
0.05
|
R
2
adj
= 0.12
|
DOR change: baseline to 12-month follow-up
|
-
|
-
|
-
|
-
|
-
|
-
|
R
2
adj
= 0.00
|
WSAS change: baseline to post-treatment
|
SF-12 MCS
|
−0.41
|
0.10
|
−0.52
|
−3.96
|
<0.001
|
R
2
adj
= 0.25
|
WSAS change: baseline to 6-month follow-up
|
SF-12 MCS
|
−0.36
|
0.11
|
−0.48
|
−3.23
|
0.00
|
R
2
adj
= 0.21
|
WSAS change: baseline to 12-month follow-up
|
SF-12 MCS
|
−0.34
|
0.12
|
−0.43
|
−2.85
|
0.01
|
R
2
adj
= 0.16
|